Market open
Fulcrum Therapeutics/$FULC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Ticker
$FULC
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
76
Website
FULC Metrics
BasicAdvanced
$217M
Market cap
-
P/E ratio
-$0.33
EPS
2.28
Beta
-
Dividend rate
Price and volume
Market cap
$217M
Beta
2.28
52-week high
$13.70
52-week low
$2.87
Average daily volume
747K
Financial strength
Current ratio
22.072
Quick ratio
21.837
Long term debt to equity
2.765
Total debt to equity
3.525
Management effectiveness
Return on assets (TTM)
-6.89%
Return on equity (TTM)
-7.37%
Valuation
Price to revenue (TTM)
2.642
Price to book
0.79
Price to tangible book (TTM)
0.79
Price to free cash flow (TTM)
-17.091
Growth
Revenue change (TTM)
2,582.55%
Earnings per share change (TTM)
-81.77%
3-year revenue growth (CAGR)
74.95%
3-year earnings per share growth (CAGR)
-49.03%
What the Analysts think about FULC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.
FULC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FULC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FULC News
AllArticlesVideos
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
GlobeNewsWire·2 days ago
Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
Accesswire·3 weeks ago
Fulcrum Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - FULC
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Fulcrum Therapeutics stock?
Fulcrum Therapeutics (FULC) has a market cap of $217M as of November 08, 2024.
What is the P/E ratio for Fulcrum Therapeutics stock?
The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of November 08, 2024.
Does Fulcrum Therapeutics stock pay dividends?
No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Fulcrum Therapeutics dividend payment date?
Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) has a beta rating of 2.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.